Valdecoxib-d3 is intended for use as an internal standard for the quantification of valdecoxib by GC- or LC-MS. Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM, for human recombinant COX-2 and COX-1, respectively).1 It decreases LPS-induced production of prostaglandin E2 in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
1.Talley, J.J., Brown, D.L., Carter, J.S., et al.4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2J. Med. Chem.43(5)775-777(2000)